SCHEMBL20064696

SCHEMBL20064696

CCOC(=O)c1cc(CC)n2nc(-c3ccccc3F)cc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.48
HSD17B10 Q99714 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.43
GAA P10253 2/20 0.42
KDM4E B2RXH2 6/20 0.41
POLB P06746 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ALOX5 P09917 1/20 0.39
CYP1A2 P05177 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20064719 0.87 MAPT (0.43) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL20064762 0.87 ADORA2A (0.42) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL20064783 0.87 ADORA3 (0.40) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL18198400 0.87 MAPT (0.44) HPGDHSD17B10ALDH1A1TP53MAPT
SCHEMBL18198479 0.86 KDM4E (0.36) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL18198475 0.86 HSD17B10 (0.42) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL18198359 0.85 KDM4E (0.43) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL18198472 0.85 KDM4E (0.39) HPGDHSD17B10ALDH1A1NPSR1TP53
SCHEMBL20064683 0.83 RAB9A (0.40) ALDH1A1MAPTGAAL3MBTL1RAB9A
SCHEMBL18198344 0.83 MET (0.42) HPGDHSD17B10ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084826-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds Janssen Sciences Ireland Unlimited Company (IE) 2021-08-10 US disclosed
US-20200223855-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2020-07-16 US disclosed
US-20190248793-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2019-08-15 US disclosed
US-10208048-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds JANSSEN SCIENCES IRELAND UC (IE) 2019-02-19 US disclosed
US-20180105529-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2018-04-19 US disclosed
US-20180105529-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS JANSSEN SCIENCES IRELAND UC (IE) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208048-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds ZC3HAV1, MAVS, TYMP HPGD 2564/4885HSD17B10 4623/4885ALDH1A1 3193/4885
US-20200223855-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS ZC3HAV1, MAVS, TYMP HPGD 2564/4885HSD17B10 4623/4885ALDH1A1 3193/4885
US-11084826-B2 RSV antiviral pyrazolo- and triazolo-pyrimidine compounds ZC3HAV1, MAVS, TYMP HPGD 2564/4885HSD17B10 4623/4885ALDH1A1 3193/4885
US-20180105529-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS ZC3HAV1, MAVS, TYMP HPGD 2564/4885HSD17B10 4623/4885ALDH1A1 3193/4885
US-20190248793-A1 RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS ZC3HAV1, MAVS, TYMP HPGD 2564/4885HSD17B10 4623/4885ALDH1A1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.